Welcome to our dedicated page for Ethos Technologies news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on Ethos Technologies stock.
Ethos Technologies Inc. reports developments tied to its digital life insurance platform, which connects consumers, independent agents and insurance carriers through online underwriting and policy issuance tools. The company distributes life insurance products in direct-to-consumer and third-party channels and earns carrier commissions and administrator-service revenue from activated policies.
Recurring updates include quarterly results, direct and third-party channel revenue, policy activation trends, and technology integrations that expand digital purchasing. Company announcements also cover carrier collaborations and product additions, including whole life, final expense, and indexed universal life offerings delivered through Ethos' platform.
aTyr Pharma, a biotherapeutics company, announced that Dr. Sanjay S. Shukla will present a corporate overview at the Jefferies London Healthcare Conference on November 15, 2022. The presentation is scheduled for 3:15 PM GMT / 10:15 AM EST in London, U.K. Following the presentation, a replay will be available on the company’s website for at least 90 days. aTyr specializes in developing first-in-class medicines via its proprietary tRNA synthetase platform, with a focus on efzofitimod, a candidate targeting fibrotic lung disease.
aTyr Pharma (Nasdaq: LIFE) announced a research collaboration with Dualsystems Biotech AG to accelerate drug discovery and enhance its proprietary tRNA synthetase platform. The exclusive partnership aims to identify 10 new target receptors for tRNA synthetases by 2025.
With over 200 issued patents, aTyr focuses on developing first-in-class medicines, including efzofitimod for fibrotic lung disease. The collaboration is expected to leverage Dualsystems’ screening technology to advance aTyr’s drug development efforts significantly.
aTyr Pharma (Nasdaq: LIFE) has announced that its CEO, Sanjay S. Shukla, will present a corporate overview at the RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium on October 7, 2022, at 11:00 AM ET. The event will feature presentations focused on pulmonary diseases, including insights from key opinion leaders and discussions about conditions like pulmonary sarcoidosis and scleroderma-associated interstitial lung disease. Access to the live webcast is available through the provided link, and a replay will be accessible for 90 days on the company website.
aTyr Pharma has received a Notice of Allowance from the USPTO for a patent covering anti-neuropilin-2 (NRP2) antibodies, which may have applications in cancer and inflammation. This patent (No. 16/376,979) includes the investigational drug ATYR2810 and represents a significant addition to aTyr's intellectual property portfolio of over 220 patents. The patent is expected to be finalized in the coming months, potentially enhancing aTyr’s position in the biotherapeutics sector.
aTyr Pharma, Inc. (Nasdaq: LIFE) has initiated the global EFZO-FIT™ Phase 3 study, evaluating efzofitimod for pulmonary sarcoidosis. This randomized, double-blind, placebo-controlled trial targets 264 patients across multiple centers in the U.S., Europe, and Japan, aiming to assess steroid-reducing effects over 52 weeks. This follows positive Phase 1b/2a results that demonstrated dose-dependent improvements in lung function and symptom relief. Efzofitimod has received FDA Orphan Drug and Fast Track designations, marking a significant step in treating this debilitating disease.
aTyr Pharma has received Fast Track designation from the FDA for efzofitimod, its lead candidate targeting systemic sclerosis-associated interstitial lung disease. This designation aims to expedite development for a significant unmet medical need, as SSc-ILD is a leading cause of death in scleroderma patients. Efzofitimod has shown promising results in clinical studies, outperforming existing treatments in reducing lung and skin fibrosis. The company plans to expand its trials into broader forms of ILD, enhancing efzofitimod's market potential.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced a corporate overview presentation by CEO Sanjay S. Shukla at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 10:00 AM EDT, located at the Lotte New York Palace Hotel. The event will feature one-on-one meetings with registered investors and a webcast available on the company’s website, with a replay lasting 90 days. aTyr focuses on first-in-class medicines derived from its proprietary tRNA synthetase platform, particularly its clinical-stage candidate, efzofitimod, for fibrotic lung disease.
aTyr Pharma, Inc. (Nasdaq: LIFE) will present a poster at the European Respiratory Society International Congress 2022 in Barcelona on September 5, 2022. The poster highlights a novel antibody for detecting neuropilin-2 (NRP2) in patient tissue samples, crucial for assessing the therapeutic potential of efzofitimod, an immunomodulator in development for pulmonary sarcoidosis and other interstitial lung diseases. This research may aid in identifying suitable patients and understanding NRP2's role in various diseases.
aTyr Pharma, Inc. (Nasdaq: LIFE) reported progress in its Phase 3 EFZO-FIT™ study for efzofitimod targeting pulmonary sarcoidosis. The FDA granted Fast Track designation for efzofitimod to expedite its development. As of June 30, 2022, the company had $89.3 million in cash and equivalents. The Phase 3 study aims to enroll 264 subjects across North America, Europe, and Japan, focusing on steroid reduction as the primary endpoint. Recent operational milestones include regulatory interactions and site selections. A conference call is scheduled for today to discuss financials and updates.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced the grant of nonstatutory stock options covering 20,600 shares at an exercise price of $3.70, matching the stock’s closing price on August 8, 2022. These options were issued to four new employees as part of the aTyr Pharma, Inc. 2022 Inducement Plan, compliant with Nasdaq Listing Rule 5635(c)(4). Options vest over four years, with 25% vesting after the first year and the remainder vesting monthly. aTyr focuses on developing therapies from its tRNA synthetase platform, particularly efzofitimod for fibrotic lung disease.